ESTRO 2024 - Abstract Book

S753

Clinical - CNS

ESTRO 2024

and brainstem interior volume≥14cc (versus <14cc) had significantly lower risk of developing ND. Cerebellum V10Gy≥0.05% (versus <0.05%) and CTV D2%≥61.4Gy (versus <61.4Gy) were found to increase the risk of 2 -year ND.

Decision curve analysis showed that the combined models had the highest net benefits at 6-month (AUC=0.79, MAE=0.035), 1-year (AUC=0.74, MAE=0.06) and 2-year (AUC=0.74, MAE=0.046) timepoints.